UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325

The use of antipsychotics in targeted therapy of schizophrenia — prospects and challenges (for example, amisulpride)

Type of Article

In the Section

Abstract

Personalized medicine is an innovative approach that takes into account the biological, social and psychological characteristics of people in the development of preventive drugs and treatment of diseases. The goals of personalized medicine in psychiatry are to anticipate a person’s susceptibility to disease, achieve accurate diagnosis, and facilitate a favorable response to treatment. This article analyzes the information presented in the literature on use of antipsychotics in treatment of schizophrenia from the standpoint of personalized medicine with the aim to draw up recommendations for improving the effectiveness of psychotic symptoms therapy and set the vector for further scientific research in this direction. Despite the existence of many international and local guidelines and protocols for antipsychotic therapy, there is still the problem of early determination of which antipsychotic will be effective and safe for a particular patient — before the most effective drug is determined, patients are usually treated with various antipsychotics. In the treatment of schizophrenia, no antipsychotic drug or dosage is universal. Therefore, to maximize the useful effect and minimize the risk of side effects, numerous individual characteristics of each individual user must be considered. In particular, such characteristics as sex, age, clinical features (dominant symptoms, time of onset of symptoms and their intensity), comorbid mental and somatic disorders, presence/absence of bad habits, response to previous therapy (in case of such) should be taken into account. Given the possibility of flexible dosage of amisulpride and its significant effectiveness in reducing various groups of symptoms in various categories of patients, it has the potential for widespread use in personalized psychiatry.

Pages

References

  1. Ozomaro U., Wahlestedt C., Nemeroff C. B. Personalized medicine in psychiatry: problems and promises // BMC medicine. 2013 Dec; 11(1): 132. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-132.
  2. Haustova O., Omelyanovych V. Modern approaches to the diagnosis and care of patients at the prodromal stage of schizophrenia // Psychosomatic Medicine and General Practice. 2020. 5(1), e0501232-e0501232.
  3. Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States / Schoenbaum M., Sutherland J. M., Chappel A. [et al.] // Schizophrenia bulletin. 2017 Apr 7; 43(6): 1262—72. DOI: https://doi.org/10.1093/schbul/sbx009.
  4. Juckel, G., & Morosini, P. The  new approach: psychosocial functioning as  a  necessary outcome criterion for therapeutic success in schizophrenia // Current opinion in psychiatry. 2008. 21(6), 630—639. DOI: https://doi.org/10.1097/YCO.0b013e328314e144.
  5. Paving the Way for Personalized Medicine: FDA’s Role in a new Era of Medical Product Development / US Department of Health and Human Services, U.S.  Food and  drug administration. October 2013, 1—61. URL: https://www.fdanews.com/ext/resources/files/10/10-28-13-Personalized-Medicine.pdf.
  6. National Research Council (US) Committee on A Framework for Developing a New  Taxonomy of  Toward Precision Medicine: Building a  Knowledge Network for  Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US); 2011. PMID: 22536618.
  7. Haustova, O.O., Assonov, D.O. Combination therapy with antipsychotics: pro et contra // NeuroNews. 2021. 1 (122), 28-33.
  8. Gender aspects in the clinical treatment of  schizophrenic inpatients with amisulpride: a  therapeutic drug monitoring study  / Müller M.  , Regenbogen B., Sachse  J. [et  al.]  // Pharmacopsychiatry. 2006 Mar; 39(02): 41—6. DOI: https://doi.org/10.1055/s-2006-931540.  PMID: 16555163.
  9. A systematic review and combined meta‐analysis of concentration of oral amisulpride  / Lin  Li, Lu  Li, De-Wei  Shang [et al.] // British Journal of Clinical Pharmacology. 2020. 86(4), 668—678. DOI: https://doi.org/10.1111/bcp.14246.
  10. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis / Huhn, , Nikolakopoulou, A., Schneider-Thoma, J. [et  al.]  // The Lancet. 2019. DOI: https://doi.org/10.1016/s0140-6736(19)31135-3.
  11. Buckley, P. F., & Miller, B. Personalized medicine for schizophrenia // npj Schizophrenia, 2017. 3(1), 2. DOI: https://doi.org/10.1038/s41537-016-0001-5.
  12. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomized, controlled, double-blind trial  / Howard, R., Cort, E., Bradley, R. [et  ]  // The  Lancet Psychiatry. 2018. 5(7), 553—563. DOI: https://doi.org/10.1016/ s2215-0366(18)30141-x.
  13. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis / Psarros, C., Theleritis,  G., Paparrigopoulos, T. J. [et al.] // International journal of geriatric psychiatry. 2009. 24(5), 518—522. DOI: https://doi.org/10.1002/gps.2146.
  14. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis / Pillinger, T., McCutcheon, R. A., Vano, L. [et al.] // The lancet. Psychiatry. 2020. 7(1), 64—77. https://doi.org/10.1016/S2215-0366(19)30416-X.
  15. Preda, A., & Shapiro, B. B. A safety evaluation of aripiprazole in  the treatment of    Expert opinion on  drug safety. 2020. 19(12), 1529—1538. DOI: https://doi.org/10.1080/14740338.2020.1832990.
  16. Safety and tolerability of antipsychotic polypharmacy / Gallego, J. A., Nielsen, J., De Hert, M. [et al.] // Expert opinion on drug safety. 2012. 11(4), 527—542. DOI: https://doi.org/10.1517/14740338.2012.683523.
  17. Personalized medicine begins with the phenotype; identifying antipsychotic response phenotypes in a first episode psychosis cohort / Mas, S., Gassó, P., Rodríguez, N. [et ]  // Acta Psychiatrica Scandinavica. 2019. DOI: https://doi.org/10.1111/acps.13131.
  18. Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments / Torrisi, S. A., Laudani, S., Contarini, G. [et ]  // Pharmaceuticals. 2020. 13(11), 365. DOI: https://doi.org/10.3390/ph13110365.
  19. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents / Miyamoto, S., Miyake, N., Jarskog, L. F. [et al.] // Molecular psychiatry. 2012. 17(12), 1206—1227. DOI: https://doi.org/10.1038/mp.2012.47.
  20. Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment / Scheggia, D., Mastrogiacomo, , Mereu, M. [et  al.]  // Nature communications. 2018. 9(1), 2265. DOI: https://doi.org/10.1038/s41467-018-04711-w.
  21. The potential role of dopamine D3 receptor neurotransmission in cognition / Nakajima, S., Gerretsen, P., Takeuchi, H. [et ] // European Neuropsychopharmacology. 2013. 23(8), 799—813.
  22. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole / Shin, S., Kim, S., Seo, S. [et al.] // Translational psychiatry. 2018. 8(1), 1—7. DOI: https://doi.org/10.1038/s41398-018-0134-6.
  23. Harrison, T. S., & Perry, C. M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder // Drugs. 2004; 64(15): 1715—36. DOI: https://doi.org/10.2165/00003495-200464150-00010.  PMID: 15257633.
  24. Casey, A. B., & Canal, C. E. Classics in chemical neuroscience: aripiprazole // ACS chemical neuroscience. 2017. 8(6), 1135—1146. DOI: https://doi.org/10.1021/acschemneuro.7b00087.
  25. Mailman, R. B., & Murthy, V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? // Current pharmaceutical design. 2010. 16(5), 488—501. DOI: https://doi.org/10.2174/138161210790361461.
  26. Lack of tolerable treatment options for patients with schizophrenia / Citrome, L., Eramo, A., Francois,  [et  al.]  // Neuropsychiatric disease and treatment. 2015. 11, 3095—3104. DOI: https://doi.org/10.2147/NDT.S91917.
  27. Pandarakalam, J. P. Combination Therapy for Treatment Resistant Schizophrenia // British Journal of Medical Practitioners. 2019. 12(2): a016.
  28. Mossaheb N. & Kaufmann R. Role of  Aripiprazole in  treatment-resistant Schizophrenia  // Neuropsychiatr Dis Treatment. 2012; 8: 235—44. DOI: https://doi.org/10.2147/NDT.S13830.
  29. Zink M., Henn A. F., Thome J. Combination of amisulpride and olanzapine in treatment resistant schizophrenia psychoses // European Psychiatry. 2004; 19: 56—58. DOI: https://doi.org/10.1016/j.eurpsy.2003.09.002.
  30. Antipsychotics: to combine or not to  combine?  / Sagud,  , Vuksan-Ćusa, B., Zivković, M. [et  al.]  // Psychiatria Danubina. 2013 Sep; 25 (3), 306—310. PMID: 24048402.
  31. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia / Leucht S., Crippa A., Siafis S. [et al.] // American Journal of Psychiatry. 2020 Apr 1; 177 (4): 342—353. DOI: https://doi.org/10.1176/appi.ajp.2019.19010034.
  32. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison  / Roh  , Chang  J.  G., Kim  C.  H. [et  al.]  // Australian & New  Zealand Journal of  Psychiatry. 2014 Jan; 48  (1): 52—60. DOI: https://doi.org/10.1177/0004867413488221
  33. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia  / Murck, H., Laughren, T., Lamers,  [et  al.]  // Innovations in clinical neuroscience. 2015 Mar-Apr; 12 (3—4), 26S—40S. PMID: 25977838.
  34. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study / Martinuzzi, E., Barbosa, S., Daoudlarian, D. [et al.] ; OPTiMiSE Study Group // Translational psychiatry. 2019. 9(1), 20. DOI: https://doi.org/10.1038/s41398-018-0366-5.
  35. Antipsychotic combinations for schizophrenia / OrtizOrendain, J., Castiello-de Obeso, S., Colunga-Lozano, E. [et al.] // The Cochrane database of systematic reviews. 2017. 6(6), CD009005. DOI: https://doi.org/10.1002/14651858.CD009005.pub2.
  36. Guinart, D., & Correll, C. U. Antipsychotic polypharmacy in schizophrenia: why not? // The Journal of clinical psychiatry. 2020. 81(3), 19ac13118.
  37. Gardner, K. N., & Bostwick, J. R. Antipsychotic treatment response in schizophrenia // American journal of health-system pharmacy // American Journal of Health-System Pharmacy. 2012. Vol. 69, Issue 21. P. 1872—1879. DOI: https://doi.org/10.2146/ajhp110559.
  38. A global measure to assess switching antipsychotic medications in the treatment of schizophrenia / Targum, S. D., Pestreich, L., Reksoprodjo, P. [et al.] // Human psychopharmacology. 2012. 27  (5), 455—463. DOI: https://doi.org/10.1002/hup.2247.
  39. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity / Schoemaker, H., Claustre, Y., Fage, D. [et al.] // Journal of Pharmacology and Experimental Therapeutics. 1997. 280(1), 83—97. PMID: 8996185.
  40. Aripiprazole for the treatment of schizophrenia in people aged 15  to  17  years. Technology appraisal guidance  [TA213]. Published date:  26 January 2011. URL: https://www.nice.org.uk/guidance/TA213.
  41. Hsu, C. W., Lee, S. Y. & Wang, L. Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan // Eur Child Adolesc Psychiatry. 2019; 28, 759— 767. DOI: https://doi.org/10.1007/s00787-018-1242-9.
  42. Rademaker M. Do women have more adverse drug reactions? // American journal of  clinical dermatology. 2001; 2  (6), 349—351. DOI: https://doi.org/10.2165/00128071-200102060-00001.
  43. Muhlberg W., Platt D. Age-dependent changes of the kidneys: pharmacological implications // Gerontology. 1999; 45 (5): 243—253. DOI: https://doi.org/10.1159/000022097.
  44. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis / Huhn M., Nikolakopoulou A. D., Schneider-Thoma J. [et al.] // The 2019; 394  (10202), 939—951. DOI: https://doi.org/10.1016/S0140-6736(19)31135-3